PAREXEL Announces Master Services Agreement with Pfizer

10 June, 2016

BOSTON, June 10, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has signed a services agreement with Pfizer Inc.  Under the terms of this agreement, PAREXEL will continue to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed.